HORSHAM, Penn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today provided an update on its competitive positioning and ongoing litigation against LaserOptek America Corp., LaserOptek Co. Ltd. (“LaserOptek Korea”), and affiliated entities including The Pinnacle Health Group and C. Dalton Internation ...

HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, highlights the substantial body of peer-reviewed clinical evidence supporting the XTRAC® Excimer Laser (308 nm) as a safe, highly effective treatment for localized atopic dermatitis, the most common f ...

Core Points - STRATA Skin Sciences, Inc. has successfully closed a registered direct offering, issuing 1,097,547 shares of common stock at a price of $2.204 per share [1][2] - The gross proceeds from this offering amounted to approximately $2.42 million, which will be utilized for working capital and general corporate purposes [2] - The offering was conducted under a shelf registration statement declared effective by the SEC on December 18, 2024, with a prospectus supplement filed on September 3, 2025 [3] Company Overview - STRATA Skin Sciences is focused on developing, commercializing, and marketing innovative products for treating dermatologic conditions, including psoriasis, vitiligo, and acne [4] - The company's product lineup features the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System [4] - STRATA employs a unique Partnership Program that offers a fee per treatment cost structure, on-site training, service and maintenance, and co-op advertising support [5]

Core Insights - STRATA Skin Sciences, Inc. has reported growth in partner clinics utilizing its Elevate 360 consulting services platform, which aims to optimize revenue through best practices in marketing, reimbursement, and patient retention [1][2][4] Group 1: E360 Program Impact - The E360 program has been adopted by 99 out of approximately 844 clinics under STRATA's XTRAC usage agreement, leading to an average growth of 7% year over year for participating clinics [4] - A partner clinic that adopted the E360 program expanded from two to nine clinics, resulting in revenue of $61,800 for STRATA in the first half of 2025, indicating significant growth potential [6] Group 2: Business Optimization - The E360 program assists clinics in managing the entire treatment process, from patient referrals to securing insurance reimbursements and scheduling follow-up visits, thereby enhancing patient retention [3][5] - STRATA's initiatives under the E360 program include turn-key marketing solutions and optimization of business systems, which have shown quick improvements in partner clinic financial performance [2][7] Group 3: Market Potential - The company anticipates continued growth opportunities from recent improvements in reimbursement policies that expand treatment indications for XTRAC lasers, including conditions like vitiligo and autoimmune skin disorders [7] - The E360 program is positioned to help clinics meet patient demand and realize market potential, suggesting a strategic focus on enhancing clinic operations and patient care [7]

Core Viewpoint - STRATA Skin Sciences, Inc. has announced a registered direct offering of 1,097,547 shares of common stock at a price of $2.204 per share, aiming to raise approximately $2.42 million for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The offering is being facilitated by Ladenburg Thalmann & Co. Inc. as the exclusive placement agent, with the closing expected around September 4, 2025, pending customary closing conditions [2]. - The gross proceeds from the offering, before deducting fees and expenses, are projected to be about $2.42 million [3]. Group 2: Company Overview - STRATA Skin Sciences is focused on developing and marketing innovative products for dermatologic conditions, including psoriasis, vitiligo, and acne, with products like the XTRAC excimer laser and TheraClearX Acne Therapy System [6]. - The company employs a unique Partnership Program that offers a fee per treatment cost structure, providing on-site training, service, maintenance, and advertising support to practices [7].

Core Insights - STRATA Skin Sciences, Inc. is a medical technology company focused on developing and marketing innovative products for dermatologic conditions [1][2] - Dr. Dolev Rafaeli, President and CEO, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025 [1] - The presentation will be available on demand for registered investors starting September 5, 2025 [2] Company Overview - STRATA specializes in in-office treatments for dermatologic conditions such as psoriasis, vitiligo, and acne [2] - Key products include the XTRAC excimer laser, VTRAC lamp systems, and TheraClearX Acne Therapy System [2] - The company employs a unique Partnership Program that offers a fee per treatment cost structure, on-site training, service and maintenance, and co-op advertising support [3]

Core Insights - STRATA Skin Sciences, Inc. is focused on expanding its market by pursuing the inclusion of expanded CPT codes for its XTRAC excimer laser treatments, targeting all inflammatory and autoimmune skin conditions, with implementation expected by January 1, 2026 [1][5] - The company emphasizes its strong patent portfolio, which provides intellectual property and market exclusivity for combination therapies, enhancing its competitive position against inferior technologies [2][3] - STRATA's patents are critical for establishing rights around combination therapies that are likely to become standard care for difficult-to-treat dermatologic conditions, positioning the company at the forefront of integrative dermatologic treatment [3][4] Patent and Technology Developments - STRATA holds three key patents related to the use of Excimer laser therapy in combination with systemic drugs, which are essential for addressing limitations in treating severe or systemic skin diseases [3][4] - The patents enable a synergistic therapeutic effect, potentially leading to enhanced treatment responses, prolonged remission, and improved safety by limiting UV exposure to affected areas [4] Market Expansion and Financial Implications - The American Medical Association's approval of updates to CPT codes will expand reimbursement eligibility for XTRAC treatments, effectively tripling the addressable patient population and improving treatment economics for providers and the company [5] - STRATA's partnership program offers a fee per treatment cost structure, which may enhance revenue opportunities and market penetration [7]

Core Insights - STRATA Skin Sciences, Inc. reported its financial results for the second quarter of 2025, highlighting a strategic focus on expanding its patient population through newly approved reimbursement codes for its XTRAC Excimer laser treatment [1][3]. Financial Performance - Revenue for Q2 2025 was $7.7 million, a decrease of 9% compared to Q2 2024 [4]. - Global recurring revenue was $5.1 million, down 4% year-over-year, while equipment revenue decreased by 18% to $2.5 million [4]. - Gross profit for the quarter was $4.3 million, representing 56% of revenue, down from $5.0 million in the same quarter of the previous year [4]. - Total operating expenses increased to $6.5 million from $5.5 million in the prior-year period [5]. - The net loss for Q2 2025 was $2.5 million, or a loss per share of $0.60, compared to a net loss of $0.1 million, or a loss per share of $0.03, in Q2 2024 [5][24]. Operational Highlights - The company is managing costs while expanding its patient pool through direct-to-consumer (DTC) efforts and strengthening partnerships with practice partners [3]. - STRATA has seen a historic expansion of CPT codes for reimbursement, effectively tripling the covered patient population in the U.S. [8]. - The average gross billings per device increased by 2.7% to $5,512 compared to the prior-year period [8]. - The company removed 21 underperforming XTRAC devices and placed 19, marking the highest number of placements in six quarters [8]. Cash Position - As of June 30, 2025, cash and cash equivalents were $6.0 million, despite a payment of $1.3 million in restricted cash related to sales tax accruals [6][8].

Core Insights - STRATA Skin Sciences is working with CMS to obtain temporary codes for expanded reimbursement of its XTRAC excimer laser treatment, aiming for implementation as early as the 2026 rule cycle [2][3] - The American Medical Association has approved updates to CPT codes, expanding reimbursement eligibility for XTRAC treatments to include various inflammatory and autoimmune skin conditions effective January 1, 2027 [2] - STRATA's efforts could potentially triple the addressable patient population, benefiting over 30 million individuals with chronic skin conditions [3] Company Developments - STRATA has received significant support from legislators, patient advocacy groups, and academic leaders, reinforcing confidence in the efficacy of Excimer Laser therapy [4] - Recent peer-reviewed studies have confirmed the safety and effectiveness of combining 308-nm excimer laser therapy with JAK inhibitors for treating vitiligo, with one study showing a 100% overall response rate [5][6] - The company is involved in ongoing litigation against LaserOptek America, with the Federal District Court agreeing to add LaserOptek Korea as a defendant, indicating potential for significant damages [7][8] Product and Market Strategy - STRATA's XTRAC excimer laser is positioned as a leading drug-free option for treating skin conditions, with a focus on enhancing patient outcomes [4][9] - The company offers a unique Partnership Program that includes a fee per treatment cost structure, on-site training, and marketing support to promote its technologies [11] - STRATA's intellectual property portfolio includes patents for localized treatment methods, positioning the company for future growth in the dermatology market [9]

Company Overview - STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing innovative products for dermatologic conditions such as psoriasis, vitiligo, and acne [5] - The company's product offerings include the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System [5] Upcoming Financial Results - STRATA will report its second quarter 2025 financial results on August 13, 2025, after the market closes [1] - A conference call will be held on the same day at 4:30 p.m. ET to review the financial results and provide updates on corporate developments [2] Conference Call Details - Interested parties can listen to the conference call by dialing 1-866-524-3160 for domestic calls or 1-412-317-6760 for international calls, with a recommendation to join approximately 10 minutes prior to the start time [3] - A telephonic replay of the call will be available until August 20, 2025, and a webcast replay will be accessible approximately one hour after the live call until February 13, 2026 [4] Partnership Program - STRATA offers a unique Partnership Program that includes a fee per treatment cost structure instead of requiring equipment purchase, installation, and use [6] - The program provides on-site training for practice personnel, service and maintenance of equipment, dedicated account and customer service associates, and co-op advertising support [6]